70
Participants
Start Date
September 26, 2019
Primary Completion Date
August 31, 2035
Study Completion Date
August 31, 2035
autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
Mattel Children's Hospital UCLA/Ronald Reagan UCLA Medical Center, Los Angeles
UCL Great Ormond Street Institute of Child Health, London
Great Ormond Street Hospital for Children NHS Foundation Trust
OTHER
University of California, Los Angeles
OTHER